Ifat Klein
10 Papers
24 Citations
Ifat Klein is an academic researcher. The author has contributed to research in topics: Medicine & Mitomycin C. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
Nir Kleinmann,Surena F. Matin,Phillip M. Pierorazio,John L. Gore,Ahmad Shabsigh,Brian Hu,Karim Chamie,Guilherme Godoy,Scott G. Hubosky,Marcelino E. Rivera,Michael A. O’Donnell,Marcus L. Quek,Jay D. Raman,John J. Knoedler,Douglas S. Scherr,Joshua Stern,Christopher J. Weight,Alon Z. Weizer,Michael Woods,Hristos Z. Kaimakliotis,Angela B. Smith,Jennifer M Linehan,Jonathan A. Coleman,Mitchell R. Humphreys,Raymond Pak,David A. Lifshitz,Michael Verni,Mehrad Adibi,Mahul B. Amin,Elyse Seltzer,Ifat Klein,Marina Konorty,Dalit Strauss-Ayali,Gil Hakim,Mark Schoenberg,Seth P. Lerner +35 more
TL;DR: Primary chemoablation of low-grade upper tract urothelial cancer with intracavitary UGN-101 results in clinically significant disease eradication and might offer a kidney-sparing treatment alternative for these patients.
125
Thermo reversible hydrogel based delivery of mitomycin C (UGN-101) for treatment of upper tract urothelial carcinoma (UTUC)
Nir Kleinmann,Grégory Johann Wirth,Jeffrey S. Lin,Surena F. Matin,Ofer Nativ,Gil Mayer,J. Alfred Witjes,Asaf Shvero,Karim Chamie,Allan J. Pantuck,Angela B. Smith,Mark Schoenberg,Nadav Malchi,Gil Hakim,Yael Agmon-Gerstein,Michal Jeshurun-Gutshtat,Ifat Klein,Helen A. Kopelen,Seth P. Lernerc +18 more
- 01 Jan 2019
TL;DR: This compassionate use program of UGN-101 demonstrates proof of concept for chemoablation treatment of upper tract urothelial carcinoma and demonstrates the safety and feasibility of increased time of the drug in the pyelocaliceal system resulting in chemoABlation of tumors.
11
Pd11-05 the chemoablative effect of vesigel instillation in patients with nmibc – preliminary results
Boris Friedman,Yoram Dekel,Andrea Tubaro,A. Ami Sidi,Benjamin Shalva,Jack Baniel,Daniel Kedar,Lorenzo Colombo,Dov Engelshtein,Edi Fridman,Ifat Klein,Michal Jeshurun,Baruch Nerotski,Dima Zolotrayov,Nadav Malchi,Joan Palou Redorta,Grégory Johann Wirth,Ilan Leibovitch,Fred Witjes +18 more
7
Lba-16 nephron-sparing management of low grade (lg) utuc with ugn-101 (mitomycin gel) for instillation: the olympus trial experience
Nir Kleinmann,Surena F. Matin,Philip Pierorazio,John C. Gore,Ahmad Shabsigh,Brian Hu,Karim Chamie,Guy Godoy,Scott G. Hubosky,Marcelino Rivera,Michael A. O’Donnell,Marcus L. Quek,Jay D. Raman,Douglas S. Scherr,Joshua M. Stern,Christopher J. Weight,Alon Z. Weizer,Michael Woods,Hristos Z. Kaimakliotis,Angela Smith VChapel,Jennifer Linehan,Jonathan A. Coleman,Mitchell R. Humphreys,Raymond Pak,David A. Lifshitz,Michael Verni,Elyse Seltzer,Ifat Klein,Mark P. Schoenberg,Seth P. Lerner +29 more
TL;DR: Data from the Olympus Trial suggest that a minimally invasive chemoablation approach utilizing UGN-101 in this population results in a high rate of initial disease eradication obviating the need for kidney removal in nearly half of treated individuals.
6
Pd19-10 the chemoablative effect of vesigel instillation in patients with nmibc – response rate and 1-year durability
Andrew T. Lenis,Karim Chamie,Boris Friedman,Andrea Tubaro,A. Ami Sidi,Daniel Kedar,Lorenzo Colombo,Dov Engelstein,Joan Palau,Grégory Johann Wirth,Ilan Leibovitch,Eddy Fridman,Ifat Klein,Michal Jeshurun,Fred Witjes +14 more
TL;DR: The HYMN trial did not show an overall difference between RITE and the control arm, however, there was a benefit for RITE in participants with papillary-only disease and RITE was well tolerated with comparable adverse events compared with BCG.
5